Genmab A GMAB
NASDAQ GMAB
$34.74 +0.21 (+0.61%)
At close: Sep 18, 2026 · 4:00 PM EDT

Genmab A (GMAB) Income towards Parent Company (2018 - 2026)

Genmab A's (GMAB) quarterly Income towards Parent Company came in at $287.0 million in Q2 2026, down 64.26% on a YoY basis from $803.0 million in Q2 2025, and down 94.95% quarter-over-quarter from $5.7 billion in Q1 2026.

Analysis

Genmab A (GMAB) Income towards Parent Company (2018 - 2026) Analysis & Trends

Genmab A (GMAB) has reported Income towards Parent Company for 9 consecutive years, with $287.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income towards Parent Company fell 64.26% year-over-year to $287.0 million; the trailing twelve-month figure through Jun 2026 stood at $12.5 billion (up 12.91% YoY), and the FY2025 full-year result was $963.0 million, down 81.25% from the prior year.
  • Income towards Parent Company declined to $287.0 million in Q2 2026 per GMAB's latest filing, from $5.7 billion in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $5.8 billion in Q3 2025 and bottomed at -$2.5 billion in Q4 2023.
  • Historically, Income towards Parent Company has averaged $2.2 billion across 5 years, with a median of $2.5 billion in 2022.
  • The sharpest annual moves came in 2023 and 2025: Income towards Parent Company slumped 3568.93% in 2023, then soared 303.27% in 2025.
  • Over 5 years, Income towards Parent Company stood at $73.2 million in 2022, then plunged by 3568.93% to -$2.5 billion in 2023, then soared by 288.86% to $4.8 billion in 2024, then grew by 19.99% to $5.8 billion in 2025, then tumbled by 95.01% to $287.0 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered $287.0 million, $5.7 billion, and $5.8 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn
10 Genmab A 2.23 Bn 728.64 Mn 1.07 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 287.00 Mn
Mar 31, 2026 5.68 Bn
Sep 30, 2025 5.75 Bn
Jun 30, 2025 803.00 Mn
Mar 31, 2025 5.30 Bn
Sep 30, 2024 4.79 Bn
Jun 30, 2024 199.12 Mn
Mar 31, 2024 4.71 Bn
Dec 31, 2023 -2.54 Bn
Sep 30, 2023 2.86 Bn
Jun 30, 2023 161.12 Mn
Mar 31, 2023 2.59 Bn
Dec 31, 2022 73.16 Mn
Sep 30, 2022 2.53 Bn
Jun 30, 2022 253.74 Mn
Dec 31, 2021 -2.27 Bn
Sep 30, 2021 2.46 Bn
Jun 30, 2021 169.09 Mn
Mar 31, 2021 1.42 Bn
Dec 31, 2020 1.67 Bn